Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.

PMID:
20606402
2.

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.

Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A.

Ann Oncol. 2010 Feb;21(2):275-82. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24.

3.

The emerging role of EpCAM in cancer and stem cell signaling.

Munz M, Baeuerle PA, Gires O.

Cancer Res. 2009 Jul 15;69(14):5627-9. doi: 10.1158/0008-5472.CAN-09-0654. Epub 2009 Jul 7. Review.

4.

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f.

PMID:
19574774
5.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

6.

Management of recurrent ovarian carcinoma: current status and future directions.

Martin LP, Schilder RJ.

Semin Oncol. 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. Review.

PMID:
19332246
7.

Nuclear signalling by tumour-associated antigen EpCAM.

Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O.

Nat Cell Biol. 2009 Feb;11(2):162-71. doi: 10.1038/ncb1824. Epub 2009 Jan 11.

PMID:
19136966
8.

Ovarian cancer.

Cho KR, Shih IeM.

Annu Rev Pathol. 2009;4:287-313. doi: 10.1146/annurev.pathol.4.110807.092246. Review.

9.

Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM.

Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O.

Front Biosci. 2008 May 1;13:5195-201.

PMID:
18508581
10.

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R.

Clin Cancer Res. 2007 Jul 1;13(13):3899-905.

11.

Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.

Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC.

Am J Pathol. 2007 Aug;171(2):386-95. Epub 2007 Jun 28. Review.

12.

Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.

Boyman O, Surh CD, Sprent J.

Expert Opin Biol Ther. 2006 Dec;6(12):1323-31. Review.

PMID:
17223740
13.

EpCAM (CD326) finding its role in cancer.

Baeuerle PA, Gires O.

Br J Cancer. 2007 Feb 12;96(3):417-23. Epub 2007 Jan 9. Review. Erratum in: Br J Cancer. 2007 May 7;96(9):1491.

14.

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG.

Gynecol Oncol. 2006 Nov;103(2):483-8. Epub 2006 May 6.

PMID:
16678891
15.

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.

Mol Immunol. 2006 Mar;43(8):1183-93. Epub 2005 Aug 15.

PMID:
16102830
16.

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.

Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE.

Cancer Res. 2004 Aug 15;64(16):5818-24.

17.

Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC.

Clin Cancer Res. 2003 Oct 15;9(13):4782-91.

18.

EpCAM: A new therapeutic target for an old cancer antigen.

Armstrong A, Eck SL.

Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6. Review.

PMID:
14508099
19.

Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.

Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R.

J Cancer Res Clin Oncol. 2003 Jun;129(6):341-8. Epub 2003 Jun 18.

PMID:
12819960
20.

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.

Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T.

Int J Cancer. 2002 Jul 1;100(1):101-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk